Antiplatelet therapy is the cornerstone of treatment in patients with coronary heart disease . Currently its medical routine for patients who received PCI take dual antiplatelet therapy of aspirin and clopidogrel. Due to genetic polymorphism and other reasons, some patients appeared clopidogrel resistance leading to poor antiplatelet effect. Ticagrelor is a new antiplatelet drug different from past P2Y12 receptor antagonis, its better oral absorption rate and bioavailability, without metabolic activation by liver enzymes showed good characteristics to inhibit platelet aggregation. Large-scale clinical studies have shown tha ticagrelor was superior to clopidogrel in patients with acute coronary syndrome. Because of its short time usage in China, the mechanism for the occurrence of dyspnea was not widely known. And the dealing experience to dyspnea is still lacking. Therefore, this paper reported 10 cases of patients with dyspnea after treatment of ticagrelor, retrieved literature finding the odds ratio for ticagrelor was 1.93 times compared with clopidogrel, and discussed the mechanism of dyspnea.